The majority of tumor-targeted therapies currently used in the clinic are comprised of antibodies or small molecule inhibitors aimed at blocking growth signaling. However, signal-blocking therapies have been ineffective in a majority of cases due to mechanisms that sustain signaling in the face of targeted treatment, highlighting a need for alternative strategies that do not rely on signal-modulation. In our previously funded project, we developed self-assembling protein-corrole constructs that circumvent the need to modulate signaling by using tumor cell surface biomarkers as portals for the targeted entry of corrole molecules. Sulfonated corroles are water soluble, macrocyclic compounds that may be metallated, spontaneously assemble with proteins, and can be cytotoxic as well as bear various photophysical properties for both imaging and diagnostics. We have shown that sulfonated corroles are membrane-impermeable yet require cytoplasmic entry to elicit cytotoxicity while remaining excluded from the nucleus. Our targeted cell penetration protein, HerPBK10, enables corrole uptake into human epidermal growth factor receptor subunit- 2 positive (HER2+) tumors via specific interaction with the HER2 dimerization partner, HER3, which is particularly represented on these cells. Receptor-binding triggers rapid endocytosis followed by endosomal escape via a membrane-lytic domain on HerPBK10, enabling corrole entry into the cytoplasm. The tumor- homing nanoparticle, HerGa, formed by assembly of HerPBK10 and a gallium metallated corrole (S2Ga or Ga- corrole), can target and ablate HER2+ tumors in mice at >10x lower dose compared to conventional chemotherapy while sparing heart and liver tissue, and with no detectable immunogenicity. Studies in recent years have now discovered that elevated cell surface levels of HER3 is associated with resistance to a number of signal-blocking breast cancer treatments, including inhibitors of EGF-R or HER1 (lapatinib), HER2 (lapatinib, trastuzumab, T-DM1), HER2-3 (pertuzumab), and combination therapy. Moreover, HER3 elevation has been identified on metastatic breast tumors, including those that spread to the brain, and on untarget-able tumors such as triple-negative breast cancer (TNBC), including TNBC with acquired resistance to EGF-R inhibition. The HER3 specificity of HerPBK10 predicts that tumor cells resisting these signal-blocking treatments are prime targets for HerPBK10-directed nanobiologics. The present study will explore this on models of resistant and metastatic breast cancer, especially those that metastasize to the brain. A regimen of using EGFR and HER2 inhibitors as adjuvants to sensitize tumors to corrole nanobiologics will be evaluated. As the median survival of patients with metastatic breast cancer is 3 years, and patients with breast cancer metastases to the brain on average survive less than one year, improved alternatives are urgently needed.

Public Health Relevance

The majority of tumor-targeted therapies currently used in the clinic are aimed at blocking signal transduction that normally supports cell growth and survival, but the majority of cases do not respond to signal-blocking therapies, while the majority of those who do initially respond develop resistance within one year. As these resistant tumors acquire mechanisms that sustain signaling in the face of targeted treatment, there is a need for alternative strategies that are not reliant on signal-modulation. This study addresses that need by introducing a nanobiologic with the capacity to not only specifically home to such resistant tumors, but also deliver toxic molecules through tumor-targeted penetration while circumventing the need to modulate signaling. Importantly, this technology also has the capacity to target metastatic tumors, including brain metastases, for which there are few options.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA140995-09
Application #
9769633
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Fu, Yali
Project Start
2009-07-01
Project End
2022-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Sims, Jessica D; Taguiam, Jan Michael; Alonso-Valenteen, Felix et al. (2018) Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. J Control Release 271:127-138
Ha, Sung Gil; Dileepan, Mythili; Ge, Xiao Na et al. (2018) Knob protein enhances epithelial barrier integrity and attenuates airway inflammation. J Allergy Clin Immunol 142:1808-1817.e3
Qu, Ying; Han, Bingchen; Gao, Bowen et al. (2017) Differentiation of Human Induced Pluripotent Stem Cells to Mammary-like Organoids. Stem Cell Reports 8:205-215
Qu, Ying; Zhou, Bo; Yang, Wei et al. (2016) Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs. Sci Rep 6:32007
Chung, Alice; Choi, Michael; Han, Bing-chen et al. (2015) Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer 15:448-457.e2
Sims, Jessica D; Hwang, Jae Youn; Wagner, Shawn et al. (2015) A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity. J Control Release 217:92-101
Medina-Kauwe, Lali K (2013) Development of adenovirus capsid proteins for targeted therapeutic delivery. Ther Deliv 4:267-77
Hwang, Jae Youn; Farkas, Daniel L; Medina-Kauwe, Lali K (2013) Analysis of targeted viral protein nanoparticles delivered to HER2+ tumors. J Vis Exp :
Hwang, Jae Youn; Lee, Jungwoo; Lee, Changyang et al. (2012) Fluorescence response of human HER2+ cancer- and MCF-12F normal cells to 200MHz ultrasound microbeam stimulation: a preliminary study of membrane permeability variation. Ultrasonics 52:803-8
Hwang, Jae Youn; Lubow, David J; Sims, Jessica D et al. (2012) Investigating photoexcitation-induced mitochondrial damage by chemotherapeutic corroles using multimode optical imaging. J Biomed Opt 17:015003

Showing the most recent 10 out of 20 publications